The registry is powered based on noninferiority principles to demonstrate equivalent cancer-specific survival rates at 5 years for AS and immediate intervention. Through 34 months of enrollment, with a median follow-up of 1 year (range, 3–32 months), 3 of 89 patients undergoing AS died of causes not related to RCC and no patient developed metastases or died of disease. Three of 187 patients undergoing immediate intervention have died, 1 of RCC. The patient who died of RCC

#selleck chemical Dovitinib keyword# had a tumor with sarcomatoid features resected with negative margins that recurred distantly. Although lacking a comparison arm, a similar prospective cohort of 82 AS patients showed one patient (1.2%) progressing to metastatic disease, seven patients (8.6%) dying of competing causes, and no patients dying from RCC over a median follow-up of 36 months.8 Although Inhibitors,research,lifescience,medical immature, results from the DISSRM Registry and similar prospective studies promise to improve our understanding and utilization of AS in select patients. Figure 1 Management algorithm for patients with small renal masses (≤ 4 cm) according to the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM). Registry protocol. 3D, three-dimensional; CBC, complete blood count; CMP, comprehensive … Selection Criteria Although a number of groups make general recommendations Inhibitors,research,lifescience,medical for the selection of patients for AS including increased age, decreased life expectancy, suitability

for surgery, and

decreased risk of metastatic disease,7,11,17 there is a paucity of data supporting or defining specific objective criteria for selection of patients for AS. Some of the important considerations include patient and tumor characteristics as they may impact life expectancy, malignant/metastatic risk, the likelihood of renal replacement Inhibitors,research,lifescience,medical therapy after treatment, and the feasibility of nephron-sparing surgery (NSS). Several studies indicate that AS is safe in the elderly18,19 and/or patients with extensive comorbidities precluding surgery.20 Prognostic models created from extirpative Inhibitors,research,lifescience,medical selleck chemical Belinostat series indicate that age and sex modulate the likelihood of having a benign SRM, with younger women and older men having an increased likelihood Anacetrapib of a benign pathology.21,22 It is also known from data extrapolated from patients with Von Hippel-Lindau disease, surgical series, and the aforementioned retrospective AS cohorts that the risks of RCC, high-grade RCC, and metastatic disease increase dramatically when tumors reach 3 cm.4,15,16,23 Tumor complexity, measured by various statistics including RENAL nephrometry score, may enable some prediction of tumor histology and grade,24 and can be used to determine the appropriateness of NSS; indeed, low-complexity tumors are generally more suitable for NSS.25 In addition, although the majority of patients present incidentally, the presence of symptoms (predominantly hematuria or flank pain) can indicate advanced disease.